Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease
- 9 November 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 75 (19) , 1702-1710
Abstract
Objectives: To evaluate in vivo brain metabolite differences in control subjects, individuals with premanifest Huntington disease (pre-HD), and individuals with early HD using 1H magnetic resonance spectroscopy (MRS) and to assess their relationship with motor performance. Methods: Eighty-five participants (30 controls, 25 pre-HD, and 30 early HD) were recruited as part of the TRACK-HD study. Eighty-four were scanned at 3 T with single-voxel spectroscopy in the left putamen. Disease burden score was >220 among pre-HD individuals. Subjects underwent TRACK-HD motor assessment including Unified Huntington9s Disease Rating Scale (UHDRS) motor scoring and a novel quantitative motor battery. Statistical analyses included linear regression and one-way analysis of variance. Results: Total N-acetylaspartate (tNAA), a neuronal integrity marker, was lower in early HD (∼15%) vs controls (p < 0.001). N-acetylaspartate (NAA), a constituent of tNAA, was lower in pre-HD (∼8%) and early HD (∼17%) vs controls (p < 0.05). The glial cell marker, myo-inositol (mI), was 50% higher in early HD vs pre-HD (p < 0.01). In early HD, mI correlated with UHDRS motor score (R2 = 0.23, p < 0.05). Across pre-HD and early HD, tNAA correlated with performance on a tongue pressure task (R2 = 0.30, p < 0.0001) and with disease burden score (R2 = 0.17, p < 0.005). Conclusions: We demonstrate lower putaminal tNAA in early HD compared to controls in a cross-section of subjects. A novel biomarker role for mI in early HD was also identified. These findings resolve disagreement in the literature about the role of MRS as an HD biomarker. We conclude that putaminal MRS measurements of NAA and mI are promising potential biomarkers of HD onset and progression.Keywords
This publication has 38 references indexed in Scilit:
- MR‐spectroscopic findings in juvenile‐onset Huntington's diseaseMovement Disorders, 2008
- MR Spectroscopy in Diagnosis and Neurological Decision-MakingSeminars in Neurology, 2008
- Detection of Huntington's disease decades before diagnosis: the Predict-HD studyJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Regional apparent metabolite concentrations in young adult brain measured by 1H MR spectroscopy at 3 TeslaJournal of Magnetic Resonance Imaging, 2008
- Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopyMovement Disorders, 2007
- Decreased frontal choline and neuropsychological performance in preclinical Huntington diseaseNeurology, 2007
- Effect of signal‐to‐noise ratio and spectral linewidth on metabolite quantification at 4 TNMR in Biomedicine, 2007
- Magnetic Resonance SpectroscopyEpilepsia, 1996
- Proton MRS in Huntington's diseaseThe Lancet, 1994
- Estimation of metabolite concentrations from localized in vivo proton NMR spectraMagnetic Resonance in Medicine, 1993